naa a22 4500 510763537 CHVBK 20180411083148.0 cr unu---uuuuu 180411e20130701xx s 000 0 eng 10.1007/s12094-012-0976-y doi (NATIONALLICENCE)springer-10.1007/s12094-012-0976-y Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma [Elektronische Daten] [N. Imai, A. Kinoshita, H. Onoda, A. Iwaku, M. Oishi, K. Tanaka, N. Fushiya, K. Koike, H. Nishino, H. Tajiri] Purpose: The pretreatment C-reactive protein (CRP) level is reported to be a prognostic indicator in patients with hepatocellular carcinoma (HCC). Methods: We investigated the prognostic implications of the changes in the CRP level after initial treatment in patients with HCC. We prospectively evaluated a cohort of 150 patients with newly diagnosed HCC. The patients were categorized into three groups: group 1 (n=120) with pre- and post-treatment CRP <1.0mg/dl, group 2 (n=5) with pre-treatment CRP ≥1.0mg/dl and post-treatment CRP <1.0mg/dl, and group 3 (n=25) with pre- and post-treatment CRP ≥1.0mg/dl. Results: The 1- and 3-year overall survival rates were 92.3 and 82.9% for group 1, 80.0 and 53.3% for group 2, and 58.8 and 4.2% for group 3. The overall survival rate for group 3 was significantly lower than that for group 1 (P<0.0001), or group 2 (P=0.003). No significant difference was found between groups 1 and 2 (P=0.627). A multi-variate analysis showed that albumin level (P=0.049), the CRP group (P<0.0001), and the Cancer of the Liver Italian Program (CLIP) score (P<0.0001) were independently associated with the overall survival. Conclusions: A persistently elevated CRP level after initial treatment is an independent marker of a poor prognosis, and normalization of the CRP level after initial treatment is associated with a better outcome in patients with HCC. Federación de Sociedades Españolas de Oncología (FESEO), 2012 C-reactive protein nationallicence Hepatocellular carcinoma nationallicence Inflammation nationallicence Prognostic marker nationallicence Imai N. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut Kinoshita A. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut Onoda H. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut Iwaku A. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut Oishi M. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut Tanaka K. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut Fushiya N. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut Koike K. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut Nishino H. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut Tajiri H. Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, 105-0003, Tokyo, Japan aut Clinical and Translational Oncology Springer Milan 15/7(2013-07-01), 575-581 1699-048X 15:7<575 2013 15 12094 https://doi.org/10.1007/s12094-012-0976-y text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0976-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Imai N. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut NATIONALLICENCE 700 1- Kinoshita A. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut NATIONALLICENCE 700 1- Onoda H. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut NATIONALLICENCE 700 1- Iwaku A. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut NATIONALLICENCE 700 1- Oishi M. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut NATIONALLICENCE 700 1- Tanaka K. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut NATIONALLICENCE 700 1- Fushiya N. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut NATIONALLICENCE 700 1- Koike K. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut NATIONALLICENCE 700 1- Nishino H. Division of Gastroenterology and Hepatology, The Jikei University Daisan Hospital, 4-11-1 Izumihon-cho, 201-8601, Komae, Tokyo, Japan aut NATIONALLICENCE 700 1- Tajiri H. Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, 105-0003, Tokyo, Japan aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/7(2013-07-01), 575-581 1699-048X 15:7<575 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer